Cyclin-Dependent Kinases 4 and 6 Inhibitors: An Emerging Therapeutic Framework from Growth Suppression to Tumor Clearance
ACS Pharmacology & Translational Science · 12.06.2026 · 9 (6) · 1263-1284
DOI: 10.1021/acsptsci.6c00005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 13.05.2026. Verfasst von Cong Ma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Breast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Health Commission of Hubei Province, National Health Commission of the People's Republic of China, Ministry of Health of the People's Republic of China.
Abstract (Originalsprache)
This review explores strategies to overcome the clinical limitations of Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors, namely, reversible cytostasis and acquired resistance. We outline an emerging therapeutic framework in which these inhibitors induce specific vulnerabilities, shifting the treatment objective from growth suppression toward tumor clearance. Specifically, we analyze the effects of CDK4/6 inhibitors across four interconnected domains: cellular senescence, compromised DNA damage repair, metabolic reprogramming, and immune microenvironment remodeling. Building upon this framework, we summarize rational combination strategiessuch as pairing with senolytics, poly-(ADP-ribose) polymerase (PARP) inhibitors, or immune checkpoint inhibitors (ICIs)designed to exploit these induced vulnerabilities. To bridge preclinical rationale with clinical application, we discuss key translational determinants, noting that successful implementation depends on biomarker-guided patient selection and optimized dosing schedules (e.g., sequential administration) to mitigate overlapping toxicities. Collectively, the evidence suggests that rational combination strategies could repurpose CDK4/6 inhibitor therapy for more durable tumor control.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Breast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, China.
ORCID-Profile: Cong Ma
Förderung
- Health Commission of Hubei Province
- National Health Commission of the People's Republic of China
- Ministry of Health of the People's Republic of China
- Department of Science and Technology of Hubei Province
- Natural Science Foundation of Wuhan
- Hubei Provincial Government
- Hubei Cancer Hospital
Zitieren
APA
Ma, C., Ji, X., Huang, W., Guo, S., Wang, L., Wu, X., Zheng, H., & Wang, J. (2026). Cyclin-Dependent Kinases 4 and 6 Inhibitors: An Emerging Therapeutic Framework from Growth Suppression to Tumor Clearance. ACS Pharmacology & Translational Science, 9(6), 1263-1284. https://doi.org/10.1021/acsptsci.6c00005
Vancouver
Ma C, Ji X, Huang W, Guo S, Wang L, Wu X, et al. Cyclin-Dependent Kinases 4 and 6 Inhibitors: An Emerging Therapeutic Framework from Growth Suppression to Tumor Clearance. ACS Pharmacology & Translational Science. 2026;9(6):1263-1284. doi:10.1021/acsptsci.6c00005
BibTeX
@article{Ma2026,
author = {Ma, Cong and Ji, Xuan and Huang, Wenqin and Guo, Senyang and Wang, Lingzi and Wu, Xinhong and Zheng, Hongmei and Wang, Jingru},
title = {Cyclin-Dependent Kinases 4 and 6 Inhibitors: An Emerging Therapeutic Framework from Growth Suppression to Tumor Clearance},
journal = {ACS Pharmacology & Translational Science},
year = {2026},
volume = {9},
number = {6},
pages = {1263--1284},
doi = {10.1021/acsptsci.6c00005}
}
EUVIMED